A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 12, 2014, Pages 2006-2013

  Otgonsuren, Munkhzul ^a   Estep, Michael J ^a   Hossain, Nayeem ^a   Younossi, Elena ^a   Frost, Spencer ^a   Henry, Linda ^a   Hunt, Sharon ^a,b   Fang, Yun ^a,b   Goodman, Zachary ^a,b   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Clinical; Epidemiology; Fatty liver disease; Identification; Model; Non invasive

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FATTY LIVER INDEX; FEMALE; HUMAN; INDEX OF NONALCOHOLIC STEATOHEPATITIS; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAFLD FIBROSIS SCORE; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BIOPSY; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM EXAMINATION; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; THEORETICAL MODEL;

ADULT; BIOPSY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; MODELS, THEORETICAL; NON-ALCOHOLIC FATTY LIVER DISEASE; PROPORTIONAL HAZARDS MODELS;

EID: 84938823524     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12665     Document Type: Article

References (35)

1. Festi D, Schiumerini R, Marzi L etal. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment. Pharmacol. Ther. 2013; 37: 392-400. doi: 10.1111/apt.12186.
2. Chalasani N, Younossi Z, Lavine J etal. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012; 107: 811-826.
3. Matteoni CA, Younossi ZM, Gramlich T etal. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
4. Ratziu V, Charlotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
5. Younossi ZM, Venkatesan C. A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. Panminerva Med. 2012; 54: 29-37. Review.
6. Bedogni G, Bellentani S, Miglioli L etal. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 1-7.
7. Seidell JC, Pérusse L, Després JP etal. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am. J. Clin. Nutr. 2001; 74: 315-321.
8. Gallagher D, Visser M, Sepúlveda D etal. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am. J. Epidemiol. 1996; 143: 228-239.
9. Dufour DR, Lott JA, Nolte FS etal. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 2000; 46: 2027-2049. Review.
10. Angulo P, Hui JM, Marchesini G etal. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
11. CDC/National Cancer for Health Statistics. National Health and Nutritional Examination Survey: analytic guidelines. Hyattsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention; Cited 28 July 2014. Available from URL: http://www.cdc.gov/nchs/nhanes/nh3data.htm
12. CDC/National Cancer for Health Statistics. National Health and Nutritional Examination Survey: laboratory data documentation (Dec 1996), Hyattsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention. Cited 28 July 2014. Available from URL: http://wonder.cdc.gov/wonder/sci_data/surveys/hanes/hanes3/type_txt/lab.asp
13. CDC/National Cancer for Health Statistics. National Health and Nutritional Examination Survey: examination data documentation (Dec 1996), Hyattsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention. Cited 28 July 2014. Available from URL: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/nhanes/nhanes3/1A/exam-acc.pdf
14. Chumlea WC, Guo SS, Kuczmarski RJ etal. Body composition estimates from NHANES III bioelectrical impedance data. Int. J. Obes. Relat. Metab. Disord. 2002; 26: 1596-1609.
15. Matthews DR, Hosker JP, Rudenski AS etal. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. CDC/National Center for Health Statistics. National Health and Nutrition Examination Survey: Procedure Manual, Hepatic Steatosis (Nov 2010), Hyattsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention. 28 July 2014. Available from URL: http://www.cdc.gov/nchs/data/nhanes/nhanes3/Hepatic_Steatosis_Ultrasound_Procedures_Manual.pdf
17. Hossain N, Afendy A, Stepanova M etal. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009; 7: 1224-1229, 1229.e1-2. doi: 10.1016/j.cgh.2009.06.007.
18. Box GEP, Tidwell PW. Transformation of the independent variables. Technometrics 1962; 4: 531-550.
19. Archer KJ, Lemeshow S. 2006. Stata Journal Volume 6 Number 1. Cited 28 July 2014. Available from URL: http://www.stata-journal.com/sjpdf.html?articlenum=st0099
20. Bedossa P, Poitou C, Veyrie N etal. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759. doi: 10.1002/hep.25889.
21. Lazo M1, Hernaez R, Eberhardt MS etal. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Epidemiol. 2013; 178: 38-45.
22. Hyysalo J, Männistö VT, Zhou Y etal. A population-based study on the prevalence of NASH using scores validated against liver histology. J. Hepatol. 2014 Apr; 60 (4): 839-846. doi: 10.1016/j.jhep.2013.12.009. Epub 2013 Dec 12
23. López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G etal. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann. Hepatol. 2014; 13: 166-178.
24. Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J. Gastroenterol. Hepatol. 2013; 28 (Suppl. 4): 64-70. doi: 10.1111/jgh.12271.
25. Finelli C, Tarantino G. Is visceral fat reduction necessary to favour metabolic changes in the liver? J. Gastrointestin. Liver Dis. 2012; 21: 205-208. Review.
26. Ayonrinde OT, Olynyk JK, Beilin LJ etal. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011; 53: 800-809. doi: 10.1002/hep.24097.
27. Petta S, Handberg A, Craxì A. Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. Curr. Pharm. Des. 2013 Feb 4; 19 (29): 5193-5218. [Epub ahead of print] PubMed PMID: 23394090.
28. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013; 62: 352-360. doi: 10.1016/j.metabol.2012.08.005.
29. Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin. Res. Hepatol. Gastroenterol. 2011; 35 (Suppl. 1): S10-20. doi: 10.1016/S2210-7401(11)70003-1.
30. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin. Radiol. 1991; 43: 26-31.
31. Layer G, Zuna I, Lorenz A etal. Computerized ultrasound B-scan texture analysis of experimental diffuse parenchymal liver disease: correlation with histopathology and tissue composition. J. Clin. Ultrasound 1999; 19: 193-201.
32. Mendler MH, Bouillet P, LeSidaner A etal. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J. Hepatol. 1998; 28: 785-794.
33. Chalasani N, Younossi Z, Lavine JE etal. AASLD PRACTICE GUIDELINE the diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Associations. Hepatology 2012; 55: 2005-2023. Cited 6 May 2014. Available from URL: http://www.aasld.org/practiceguidelines/Documents/NonalcoholicFattyLiverDisease2012_25762_ftp.pdf
34. Loria P, Adinolfi LE, Bellentani S etal. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig. Liver Dis. 2010; 42: 272-282.
35. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.